Clinical Trials Browser

Phase 3 × Interventional × Ovarian Neoplasms × Clear all

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT03519230 2026-03-16

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT03842982 2026-03-16

CHIPPI

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT07214779 2026-03-16

MAESTRA 2

Phase 3 Recruiting

Ovarian Neoplasms

NCT04729387 2026-03-13

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3 Terminated

Ovarian Neoplasms

NCT06824467 2026-03-13

TroFuse-022

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07318558 2026-03-13

TroFuse-021

Phase 3 Recruiting

Ovarian Neoplasms

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Phase 3 Active not recruiting

733 enrolled 21 charts 2 FDA

Ovarian Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

Phase 3 Active not recruiting

643 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Active not recruiting

579 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04575935 2026-03-05

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06819007 2026-03-05

DO-01

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT07225270 2026-03-03

RAINFOL-04

Phase 3 Recruiting

Ovarian Neoplasms

NCT04884360 2026-03-02

MONO-OLA1

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT06915025 2026-02-27

OVATION-3

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05445778 2026-02-23

GLORIOSA

Phase 3 Recruiting

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT05316181 2026-02-12

KOV-HIPEC-02R

Phase 3 Active not recruiting

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT04169997 2026-01-28

FLAMES

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT03937154 2026-01-27

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Phase 3 Active not recruiting

BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms

NCT07286162 2026-01-27

CALM-TF

Phase 3 Not yet recruiting

Ovarian Neoplasms, Recurrence

NCT04421963 2026-01-21

ROSY-O

Phase 3 Active not recruiting

BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms

NCT04095364 2026-01-14

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06580314 2026-01-14

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Phase 3 Recruiting

Ovarian Neoplasms

NCT03602859 2025-12-31

FIRST

Phase 3 Active not recruiting

1,400 enrolled 18 charts

Ovarian Neoplasms

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3 Active not recruiting

1,052 enrolled 27 charts

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT05659381 2025-12-24

HOTT

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06963268 2025-12-19

SENTOV II

Phase 3 Recruiting

Ovarian Neoplasms

NCT06855069 2025-12-17

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Phase 3 Recruiting

Ovarian Neoplasms

NCT07286266 2025-12-16

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Phase 3 Not yet recruiting

Ovarian Neoplasms

NCT01844986 2025-12-10

SOLO-1

Phase 3 Active not recruiting

450 enrolled 18 charts 1 FDA

Pathologic Complete Response, Ovarian Neoplasms

NCT03815643 2025-12-04

Avelumab Program Rollover Study

Phase 3 Active not recruiting

GenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Ovarian Neoplasms

NCT06007586 2025-12-04

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

Phase 3 Completed

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Vomiting, Endometrial Neoplasms

NCT01081262 2025-11-25

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Phase 3 Active not recruiting

50 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01223248 2025-11-04

Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

Phase 3 Active not recruiting

DermatologicGynecologicSarcoma

Melanoma, Ovarian Neoplasms, Sarcoma, Pyloric Stenosis, Hypertrophic

NCT03740165 2025-10-22

KEYLYNK-001

Phase 3 Active not recruiting

1,367 enrolled 29 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT06817161 2025-10-07

ESTANVO

Phase 3 Recruiting

Digestive System Diseases, Ovarian Neoplasms

NCT05804370 2025-10-01

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

Phase 3 Recruiting

Ovarian Neoplasms

NCT04908787 2025-09-11

A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

Phase 3 Completed

Ovarian Neoplasms

NCT05009082 2025-09-10

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04534075 2025-09-08

FIDURA

Phase 3 Completed

GastrointestinalGenitourinaryGynecologic

Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Flatulence, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Rectal Neoplasms

NCT05092360 2025-08-28

ARTISTRY-7

Phase 3 Terminated

456 enrolled 19 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01874353 2025-08-03

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Phase 3 Active not recruiting

327 enrolled 21 charts 1 FDA

Ovarian Neoplasms

NCT07068464 2025-07-16

ICRA

Phase 3 Not yet recruiting

Ovarian Neoplasms

NCT03863860 2025-07-03

A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Phase 3 Completed

Ovarian Neoplasms

NCT05059522 2025-06-25

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT04878094 2025-05-30

A Study of Intra-operative Imaging in Women With Ovarian Cancer

Phase 3 Recruiting

Ovarian Neoplasms

NCT06990503 2025-05-25

SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer

Phase 3 Not yet recruiting

Ovarian Neoplasms

NCT05257408 2025-04-16

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Phase 3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03353831 2025-04-06

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Phase 3 Completed

Ovarian Neoplasms

NCT02891824 2025-02-11

ATALANTE

Phase 3 Completed

Ovarian Neoplasms